Superior survival of young women with malignant melanoma. Commentary.
The Commission on Cancer data from the National Cancer Data Base (NCDB) relating to patients with malignant melanoma are used to examine patterns of long-term survival by patient gender and age, stage of disease, disease morphology, and anatomic subsite.
Five calls for data have yielded more than 3,700,000 cases of cancer for the years 1985 through 1993, including 23,341 cases of malignant melanoma between 1985 and 1989, from hospital cancer registries across the US, representing slightly less than a quarter of all melanoma cases diagnosed in the US between 1985 and 1989.
Three statements can be made from this data : (1) There is little difference in the frequency of malignant melanoma between men and women with respect to stage of disease or morphology.
However, differences between the genders do appear with respect to the anatomic subsite of melanotic tumors. (2) Overall, young women (45 years of age and under) enjoy superior survival rates when compared with older women (55 years of age and older) and men of any age. (3) The survival advantage held by young women is particularly pronounced among patients diagnosed with advanced stage disease.
These data suggest that factors present in younger women may be critical in the superior survival rates seen among premenopausal women and might be hormonal in nature.
Mots-clés Pascal : Mélanome malin, Evaluation, Survie, Effet biologique, Sexe, Activité biologique, Hormone stéroïde sexuelle, Etude cohorte, Homme, Tumeur maligne, Peau pathologie, Epidémiologie
Mots-clés Pascal anglais : Malignant melanoma, Evaluation, Survival, Biological effect, Sex, Biological activity, Sex steroid hormone, Cohort study, Human, Malignant tumor, Skin disease, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0312401
Code Inist : 002B08A. Création : 27/11/1998.